A Phase 2 interventional study of Ticagrelor and Comparator in Peripheral Artery Disease (PAD), sponsored by AstraZeneca. Terminated at 10 sites in United States. Open to participants aged 50 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-07-19.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ticagrelor in Peripheral Arterial Disease — 1 open to participants now, 2 under way, none of them phase 3. Ticagrelor · Peripheral Arterial Disease.
Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, this one is the 7th largest by enrollment, is one of 3 that started in 2014, is the only one in phase 2, and was the 3rd registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →1 of the 10 studies testing ticagrelor in Peripheral Arterial Disease is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 50 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 4 · Phase 4 2
First in 2012; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 58 across the 10 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 7 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
1 of the studies testing ticagrelor in Peripheral Arterial Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing ticagrelor in Peripheral Arterial Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of PAD confirmed by history and any one of the following observed in the index (intervention) leg at the Screening Visit:
Exclusion Criteria
Clinical necessity to use the following restricted concomitant medications within 4 weeks prior to randomisation. Patients taking any of these medications at the Screening Visit may be considered for randomisation after a 4 week from the medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
Drug: Ticagrelor
26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
Drug: Comparator
Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
Also known as: Brilinta
Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Also known as: Aspirin
Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)
Time frame: 26 Weeks
Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)
Time frame: 26 Weeks
A total of 71 subjects were screened at 16 centers throughout the United States of America (USA). First subject enrolled: 20Oct2014. Last subject last visit: 23May2016. Date of early study termination: 21Oct2015
| Milestone | Ticagrelor | Aspirin |
|---|---|---|
| Started | 16 | 24 |
| Sujects who received treatment | 16 | 24 |
| Sujects who completed treatment | 10 | 17 |
| Completed | 14 | 20 |
| Not completed | 2 | 4 |
| Withdrew: No evr/not pad/pi decision/rle bypass | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| log(Second) | Ticagrelor | Aspirin |
|---|---|---|
| Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET) | 0.0 (-0.2 to 0.2) | 0.1 (-0.0 to 0.3) |
| log(Second) | Ticagrelor | Aspirin |
|---|---|---|
| Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET) | 0.6 (0.1 to 1.1) | 0.5 (0.1 to 0.8) |
Collected over 26 weeks treatment period + 30 days followup. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ticagrelor | — | 4/16 (25%) | 1/16 (6.3%) |
| Aspirin | — | 2/24 (8.3%) | 1/24 (4.2%) |
| Event | Ticagrelor | Aspirin |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 1/16 | 0/24 |
| SyncopeNervous system disorders | 1/16 | 0/24 |
| HaemorrhageVascular disorders | 1/16 | 0/24 |
| HypotensionVascular disorders | 1/16 | 0/24 |
| CellulitisInfections and infestations | 0/16 | 1/24 |
| OsteomyelitisInfections and infestations | 0/16 | 1/24 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/16 | 1/24 |
| Peripheral artery stenosisVascular disorders | 0/16 | 1/24 |
| Event | Ticagrelor | Aspirin |
|---|---|---|
| Procedural haemorrhageInjury, poisoning and procedural complications | 1/16 | 0/24 |
| Arterial occlusive diseaseVascular disorders | 0/16 | 1/24 |
All randomised subjects with the exception of one subject who did not undergo EVR.
| Age, Continuous(years) | Ticagrelor | Aspirin | Total |
|---|---|---|---|
| Mean | 69.1 ± 9.15 | 67.0 ± 8.31 | 67.9 ± 8.60 |
| Sex: Female, Male(Participants) | Ticagrelor | Aspirin | Total |
|---|---|---|---|
| Female | 9 | 9 | 18 |
| Male | 7 | 15 | 22 |
| Ethnicity (NIH/OMB)(Participants) | Ticagrelor | Aspirin | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 13 | 21 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Ticagrelor | Aspirin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 2 | 6 |
| White | 11 | 20 | 31 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 3 |
Ran from Oct 2014 to primary completion in May 2016, 19 months.
Results were first posted in Jun 2017, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor